Related by context. All words. (Click for frequent words.) 63 pT2 62 TRUS 62 histologic subtype 60 Retreatment 60 transabdominal 60 thyroglobulin 60 gastric adenocarcinoma 60 Immunohistochemical staining 60 endoscopic ultrasonography 60 pathologic diagnosis 60 intraepithelial neoplasia 60 surgically resectable 59 papillary thyroid carcinoma 59 urothelial carcinoma 59 LV ejection fraction 59 pT3 59 CIN2 + 59 total thyroidectomy 59 T1a 59 urothelial 59 laparoscopic radical nephrectomy 59 peritoneal carcinomatosis 58 histopathologic examination 58 surgically resected 58 CTEPH 58 thymoma 58 radical prostatectomy RP 58 renal cysts 58 seminal vesicle invasion 58 extracranial 58 metaplasia 58 null mice 58 reflux esophagitis 58 ultrasonographic 58 immunostaining 58 squamous intraepithelial lesions 58 CC genotype 58 immunoreactive 58 allelic variants 58 FDG PET imaging 57 diastolic velocity 57 basal cell carcinoma BCC 57 completely resected 57 hepatocellular carcinomas 57 intravesical therapy 57 cytologic 57 HGPIN 57 #m Tc 57 SSc 57 enterococcal 57 cervical carcinoma 57 prostate cancer CaP 57 immunoblotting 57 histological subtype 57 pretest probability 57 RARP 57 syngeneic 57 histologically confirmed 57 mutated K ras 57 lymphadenectomy 57 angiographically 57 metastatic malignant 57 dinucleotide 56 idiopathic membranous nephropathy 56 LRTI 56 histologically proven 56 polyposis 56 hyperplastic 56 mediastinitis 56 colorectal adenoma 56 atrioventricular block 56 clinicopathological features 56 debulking surgery 56 renal biopsy 56 TIMP 56 NMIBC 56 TT genotype 56 underwent resection 56 mesangial 56 Fully Covered Stent 56 metastatic gastric 56 T1c 56 squamous cell carcinoma SCC 56 Histological 56 rs# [004] 56 prognostic significance 56 neoplasias 56 submucosal 56 HLA A2 56 follicular thyroid cancer 56 Kruskal Wallis test 56 IIIA NSCLC 56 Endometrial 56 endoscopic resection 56 carcinoembryonic antigen 56 mITT population 56 Haplotype 56 cTnI 56 CLL SLL 56 COL#A# 56 definite stent thrombosis 56 femoral neck fracture 56 situ LCIS 56 extracapsular extension 55 hemoglobin Hb 55 laparoscopic partial nephrectomy 55 multimodality therapy 55 genotypic resistance 55 supratentorial 55 coronary stenosis 55 microsatellite instability 55 gastroduodenal 55 bronchial epithelial cells 55 hepatoma 55 histologic findings 55 cystoid macular edema 55 Fontan procedure 55 intrahepatic 55 Annexin V 55 tumorigenicity 55 CIN3 55 papillary renal cell carcinoma 55 invasive carcinomas 55 undergoing radical cystectomy 55 lymphovascular invasion 55 isoprostane 55 T SPOT.TB 55 HER2 amplification 55 embryonal carcinoma 55 radical cystectomy 55 microbiologically evaluable 55 CsA 55 radical nephrectomy 55 NOD SCID mice 55 PNET 55 transrectal ultrasound guided 55 undetectable HBV DNA 55 Alkaline Phosphatase 55 FDG-PET/CT 55 percutaneous vertebroplasty 55 Histologic 55 transurethral 55 FDG PET scan 55 renal tumors 55 scintigraphic 55 nodal metastases 55 prostatic adenocarcinoma 55 pretreatment serum 55 Familial Hypercholesterolemia 55 biopsy Gleason 55 HepDirect prodrug 55 preconcentration 55 grade squamous intraepithelial 55 tPSA 55 gene polymorphism 55 LV dysfunction 55 multivariable analysis 55 pleurodesis 55 cytoreductive nephrectomy 55 IL#B 55 bone scintigraphy 55 μg ml 55 thyroid carcinoma 55 PCa 55 antibiotics metronidazole 55 immunohistochemical analysis 55 T2 lesions 54 bladder carcinoma 54 SNP rs# [002] 54 digital subtraction angiography 54 CRp 54 transthoracic echocardiography 54 malignant nodules 54 TIMP 1 54 metabolomic profiles 54 myocardial revascularization 54 independent prognostic marker 54 immunoreactivity 54 ileal 54 immunohistochemical 54 multivariate analyzes 54 Evaluable 54 clinicopathologic 54 metastatic lymph nodes 54 advanced adenoma 54 Western blotting 54 adenocarcinomas 54 efficacy evaluable 54 stage IIIB 54 mediastinal lymph nodes 54 coexpression 54 TURBT 54 mononuclear 54 colorectal adenocarcinoma 54 pain palliation 54 TKAs 54 elevated transaminases 54 thymidine kinase 54 Estrogen Receptor 54 stratifying patients 54 ABL1 54 extranodal 54 AST ALT 54 biliary tract cancer 54 Histopathological 54 sonographically 54 hydronephrosis 54 Preoperatively 54 abacavir Ziagen 54 IIIb 54 HSCT 54 elevated troponin 54 protein tyrosine phosphatase 54 intact parathyroid hormone 54 HER2 expression 54 somatostatin analog 54 serum bilirubin 54 pretransplant 54 seminal vesicle 54 nonmetastatic 54 DAS# remission 54 osteochondromas 54 pancreatectomy 54 biochemical relapse 54 homozygotes 54 endometrioid 54 -#.# ± [002] 54 mITT 54 relapsed MM 54 interstitial brachytherapy 54 crossclamp 54 ALT elevations 54 ISOCOUNTRY3 54 trypsin digestion 54 RIGScan R 54 STRIDE PD 54 μg liter 54 Multivariate analysis 54 Papillary 54 mucinous 54 Nasopharyngeal 54 hip resurfacing arthroplasty 54 prostate carcinoma 54 hilar 54 heterozygotes 54 zotarolimus 54 clinicopathological 54 euthyroid 54 histopathological 54 fig. S2 54 SUVmax 54 IntroductionThe 54 acid EDTA 54 mediated inhibition 54 Shc 54 cytogenetic abnormalities 54 Genomic Grade 54 PCNL 54 aortic root replacement 54 transvaginal sonography 54 microvessel density 54 histopathologic findings 54 CD# CD# 54 ^ sup ^ 54 micrometastasis 53 hyperintensities 53 LVNC 53 intraobserver 53 acute cholecystitis 53 BRAF V#E mutation 53 unfavorable cytogenetics 53 steroidogenic 53 Cypher Stent 53 EGFP 53 adnexal mass 53 antimicrobial susceptibility testing 53 serological markers 53 aminotransferase 53 intramedullary nailing 53 depsipeptide 53 PHPT 53 Human Leukocyte Antigen 53 Cytogenetic 53 Dynabeads 53 Quantitation 53 guaiac 53 myocardial necrosis 53 ertapenem 53 symptomatic DVT 53 RRM1 53 parenchymal 53 osteopenic 53 HOXB# 53 demyelinating 53 multivariate Cox 53 = #.#-#.# 53 seropositivity 53 Lymphoid 53 Oncotype DX Recurrence Score 53 chemoradiotherapy 53 clinico pathological 53 μmol L 53 Supplementary Table 53 serum ALT 53 Appropriateness Criteria 53 lymphocytosis 53 adenoma recurrence 53 oncologic outcomes 53 Adaptive Radiation Therapy 53 elevated LDH 53 obscure gastrointestinal bleeding 53 Histopathologic 53 receptor antagonism 53 hepatic cirrhosis 53 nasopharyngeal swabs 53 cardiac perfusion 53 NFV 53 neurological manifestations 53 radiologically 53 type natriuretic peptide 53 breast carcinoma 53 histopathologic 53 intestinal metaplasia 53 transthoracic 53 prostate cancer PCa 53 paroxysmal AF 53 epithelial tumors 53 antiangiogenic agent 53 MR angiography 53 infiltrating ductal carcinoma 53 p = #.# [003] 53 ER CHOP 53 degenerative lumbar 53 Microwave Ablation System 53 invasive carcinoma 53 MBq 53 pCR 53 BPS IC 53 gastric carcinoma 53 ESR1 53 LB# [003] 53 Injury Severity Score 53 serum alkaline phosphatase 53 interobserver 53 Common Toxicity Criteria 53 lumbar spine BMD 53 Rating Scale BPRS 53 #OHD 53 symptomatic paroxysmal AF 53 node metastases 53 cytochrome c oxidase 53 intracardiac 53 carotid stenosis 53 pelvic lymphadenectomy 53 carboxypeptidase 53 docetaxel pretreated 53 MTT assay 53 ano genital warts 53 Microarray analysis 53 colorectal carcinoma 53 genes differentially expressed 53 paragangliomas 53 intraventricular 53 cutaneous squamous cell carcinoma 53 Symptom Checklist 53 Subgroup analysis 53 endoscopic retrograde cholangiopancreatography ERCGrant Parpan 53 metastatic malignant melanoma 53 somatostatin receptor 53 ADPKD 53 linkage disequilibrium LD 53 operable breast cancer 53 HER2 overexpression 53 giant cell arteritis 53 HNSCC 53 HRCT 53 observational cohort study 53 CORE OM 53 pleural fluid 53 Activity Assay 53 thiopurine 53 caspofungin 53 SNP rs# [001] 53 ERBB2 53 Fine needle aspiration 53 lymphoproliferative disorders 52 pathologic examination 52 target lesion revascularizations 52 antibody titer 52 univariate analysis 52 REVIVE Diabetes 52 statistical significance p 52 ASCUS 52 HepG2 cells 52 cinacalcet 52 Leydig cell 52 eNO 52 #β estradiol 52 C. trachomatis 52 mg p = 52 iPTH 52 phosphorylase 52 prospectively enrolled 52 peripheral arterial 52 advanced adenomas 52 MVA MUC1 IL2 52 T2DM 52 grade cervical intraepithelial 52 differential gene expression 52 esophageal carcinoma 52 hip arthroplasty 52 radioligand 52 fluoropyrimidine 52 specific alkaline phosphatase 52 umbilical artery 52 EGFR mutated 52 Endoscopic ultrasound 52 Nb Ta 52 Comparators 52 Elevated serum 52 Hexvix ® 52 TGZ 52 leiomyomas 52 follicular lymphoma FL 52 paraprotein 52 chronic urticaria 52 CEUS 52 Pharmacokinetic studies 52 promoter methylation 52 folate receptor 52 NS3 52 NSABP B 52 dorsal root ganglion 52 CYP #D# 52 clinically evaluable CE 52 plasmacytoid 52 refractory ovarian cancer 52 variant allele 52 LHRH receptor positive 52 periventricular 52 haematological cancers 52 Figure 1C 52 cagA 52 moderately emetogenic 52 % Confidence Interval 52 quantitative computed tomography 52 drotrecogin alfa activated 52 alveolar epithelial cells 52 Adenomas 52 multivariable Cox 52 fasting plasma 52 DU# [002] 52 leucopenia 52 ECLS 52 epithelial ovarian cancer 52 ^ sup #m 52 CHAMPION PCI 52 urodynamic 52 prognostic biomarker 52 obstructive coronary artery 52 colonoscopic 52 P ≤ 52 urethral stricture 52 Eisenmenger syndrome 52 serum biomarker 52 MYBPC3 52 penetrance 52 prospective multicenter study 52 CP CPPS 52 C#BL 6 mice 52 radical retropubic prostatectomy 52 fluticasone propionate FP 52 1beta 52 kDa protein 52 cannulated 52 neoadjuvant treatment 52 Resection 52 dyspnoea 52 D Dimer 52 ErbB2 positive 52 haematologic 52 Acute Coronary Syndromes ACS 52 doxorubicin docetaxel 52 degranulation 52 locoregional recurrence 52 invasive lobular carcinoma 52 nodal metastasis 52 atypical hyperplasia 52 Lymph node 52 prostate adenocarcinoma 52 Mobile Metal Ions 52 Distal 52 pg ml 52 alkaline phosphatase 52 papillary carcinoma 52 echocardiographic parameters 52 LPS induced 52 eosinophilia 52 histologic diagnosis 52 HLA DRB1 * 52 GH deficiency 52 saphenous vein graft 52 Immunohistochemical analysis 52 myocardial viability 52 human leukocyte antigen HLA 52 preserved LVEF 52 murine model 52 JETSTREAM G3 52 adjuvant cisplatin 52 nodal dissection 52 Stage IIIb 52 recurrent UTI 52 Type IIa 52 pmol 52 DAS# scores 52 SCr 52 Proliferative 52 conjugated equine estrogen 52 external beam radiotherapy 52 stellate ganglion block 52 EBRT 52 extensive metabolizers 52 mL/min/#.# m 2 52 nephrogenic 52 endoscopic mucosal resection 52 Cr#O# 52 dose dependently 52 bivariate 52 glucocorticoid induced 52 Adenocarcinoma 52 Figure 1A 52 HCCs 52 xenograft model 52 thromboemboli 52 HCV replicon 52 Cinacalcet HCl 52 IPAH 52 squamous 52 histologic examination 52 deoxyglucose 52 liposome formulation 51 TNM staging 51 PSA nadir 51 mRCC 51 transthyretin amyloidosis 51 Endeavor DES 51 % CI #.#-#.# [007] 51 Kaplan Meier analysis 51 biochemical recurrence 51 CIN3 + 51 germline mutation 51 pharmacodynamic PD 51 SensoLyte ™ 51 Ectopic 51 autologous SCT 51 % CI #.#-#.# [008] 51 TAXUS Liberté stent 51 ABCB1 51 Quantitative RT PCR 51 left ventricular LV 51 null responder 51 functional mitral regurgitation 51 ovarian carcinoma 51 intraperitoneally 51 adrenocortical 51 isoenzyme 51 metastatic bladder 51 posttreatment 51 lesional 51 immunofluorescence staining 51 BI RADS 51 P = .# 51 R0 resection 51 baseline LDH 51 CZP 51 indolent lymphomas 51 db db mice 51 airway hyperresponsiveness 51 reactive hyperemia 51 lymph node metastasis 51 ELISPOT 51 pancreatic ductal 51 Squamous 51 visceral metastases 51 tipranavir r 51 bronchoalveolar lavage fluid 51 Apolipoprotein 51 CMML 51 pelvic lymph node dissection 51 Oropharyngeal 51 NSTE ACS 51 monocytic 51 NTx 51 mutational analysis 51 PLAT 51 Subgroup analyzes 51 pN 51 Ablation System 51 normal karyotype 51 logistic regression analysis 51 endoluminal 51 ligand induced 51 VATS lobectomy 51 TRAS 51 Cardiac Troponin 51 trophoblast cells 51 Desorption 51 Vascugel ® 51 urodynamic parameters 51 antiretroviral naïve 51 TRUS biopsy 51 plasma pharmacokinetics 51 M1 muscarinic 51 Chemoradiation 51 SLN biopsy 51 prospectively randomized 51 Early Joli Fou 51 p# antigen 51 ECG gated 51 intracranial hemorrhage ICH 51 chemiluminescence 51 fluorite mineralization 51 nasal polyposis 51 pertussis toxin 51 hepatic fibrosis 51 meniscectomy 51 ß blockers 51 ALT elevation 51 transcranial Doppler ultrasound 51 Prospective Randomized 51 Valvular 51 interleukin IL -# 51 N acetyl 51 ara C 51 Polymorphisms 51 sargramostim 51 mg BID dose 51 renal cell carcinomas 51 myeloperoxidase 51 Corynebacterium 51 symptomatic intracranial hemorrhage 51 CR CRu 51 macroalbuminuria 51 triiodothyronine 51 cytological 51 creatinine ratio 51 OsseoSpeed 51 Cepheid Xpert 51 adenoma 51 von Willebrand 51 bronchial hyperresponsiveness 51 urolithiasis 51 HDACi 51 etiologic 51 gamma glutamyl 51 Fkft 51 adiponectin concentrations 51 Zinc Zn 51 binary restenosis 51 PO4 51 annexin V 51 RENAL 51 laser Doppler 51 small lymphocytic lymphoma 51 Polymorphism 51 NOD mouse 51 sensory neuropathy 51 radiotherapy RT 51 NuroPro PD 51 mg/m2 cohort 51 clinically evaluable 51 Angiographic 51 morphometric vertebral fractures 51 interferon γ 51 nucleotide substitutions 51 immunofluorescent 51 colorectal neoplasms 51 FT4 51 symptomatic VTE 51 TECNIS ® 51 F FDG PET 51 PTI CORR 51 tTG 51 7AR 51 recurrent DVT 51 GSTP1 51 metastatic renal cell carcinoma 51 preoperative PSA 51 CCyR 51 CEACAM1 51 μg mL 51 Mohs micrographic surgery 51 Tomographic 51 sleeve lobectomy 51 undergoing coronary angiography 51 lysate 51 BEXXAR Therapeutic Regimen 51 F FLT 51 TMPRSS2 ERG fusion 51 EGFR mutation positive 51 pDC 51 Postoperatively 51 TAXUS Express Stent 51 chromosome #p# [002] 51 Peripheral Arterial 51 TLIF 51 inotropic 51 umbilical vein 51 diffusivity 51 periprocedural MI 51 pg mL 51 prostatic tissue 51 proximal femoral 51 bronchopulmonary 51 BALF 51 lymphocytic leukemia 51 radionuclide imaging 51 hemangioblast 51 noninferiority 51 pilocytic astrocytomas 51 malignant ascites 51 Axillary 51 PLND 51 Medullary thyroid cancer 51 Pearson correlation coefficient 51 RAS mutations 51 % CI #.#-#.# [001] 51 tissue oxygenation 51 Radiographic 51 constitutively active 51 Thal Dex 51 OPCAB 51 sirolimus stent 51 de novo AML 50 AtherOx 50 Annexin 50 ICD CRT 50 mdec #-# 50 biliary stones 50 VERSANT 50 hypercalciuria 50 posterolateral fusion 50 distinct subtypes 50 lysophosphatidic acid 50 Troponin 50 kidney allograft 50 Langerhans cell histiocytosis 50 autogenous 50 seronegative 50 pmol L 50 immunocompetent 50 dyssynchrony 50 constipation predominant IBS 50 ERK signaling 50 p# biomarker 50 PaO 2 50 transrectal ultrasound 50 mutational status 50 systolic dysfunction 50 penetrant 50 HBV genotypes 50 mean ± SEM 50 achieved CCyR 50 intestinal permeability 50 SERCA2a 50 florbetaben 50 Cardiorespiratory fitness 50 selective agonist 50 serous ovarian cancer 50 haematopoietic 50 Antisoma AS# 50 QT Prolongation 50 low expressors 50 neovascular 50 anogenital warts 50 PSMA ADC 50 osteoid osteoma 50 fludarabine cyclophosphamide 50 mCRPC 50 thrombocytosis 50 tumor infiltrating lymphocytes 50 fosbretabulin 50 HOMA IR 50 T#I [002] 50 nucleolar 50 colorimetric 50 ZACTIMA 50 transaminase levels 50 Renal Cell Carcinoma RCC 50 CellSearch ™ 50 Thrombolysis 50 prucalopride 50 hip BMD 50 beta blocker therapy 50 estrogen receptor ER 50 TEC #OL 50 Stratification 50 biologic DMARD 50 germline mutations 50 ABSORB trial 50 β blockers 50 Supplementary Appendix 50 lymphocyte count 50 HBeAg seroconversion 50 mitral stenosis 50 BoNT 50 alkaline phosphatase ALP 50 mol L 50 Supplemental Figure 50 posterolateral 50 tumor regressions 50 mRNA expression 50 polyomavirus 50 losing enteropathy 50 antithrombotic therapy 50 Protease Inhibitors 50 Subtype 50 ERalpha 50 dosimetric 50 androgen blockade 50 parous women 50 cat dander allergy 50 K ras mutations 50 pediatric acute lymphoblastic 50 esophageal squamous cell carcinoma 50 BMP2 50 statistically significant p = 50 interrater 50 refractory colorectal cancer 50 Confirmatory 50 interobserver reliability 50 Mutational 50 extrapleural pneumonectomy 50 Pt Pd Au 50 2n = 50 ascites fluid 50 histone acetyltransferase 50 Allogeneic 50 bronchioloalveolar carcinoma 50 Oncotype 50 multicentre randomized 50 EQ 5D 50 neoplasm 50 postoperative radiotherapy 50 endometrial biopsies 50 QT QTc 50 advanced pancreatic neuroendocrine 50 renal allograft 50 Contrast Enhancement 50 QuadraSphere 50 HepaSphere Microspheres 50 Streptococcus agalactiae 50 noncardiac 50 hyperhomocysteinemia 50 Phylogenetic analyzes 50 metabolite concentrations 50 fusion XRF 50 ductal lobular 50 powder diffraction 50 MR spectroscopy 50 Dacogen decitabine 50 hyperoxaluria 50 B Cell Lymphoma 50 MMSE score 50 somatoform disorders 50 proximal femur 50 g mL 50 inhibits VEGF 50 cytotoxic T lymphocyte 50 HIV seropositive 50 FVT 50 CIME 50 gadobutrol 50 PreDx DRS 50 muscarinic receptor 50 cell lysate 50 unfractionated heparin UFH 50 Mineral Resource estimation 50 stably transfected 50 murine monoclonal antibody 50 Prostate specific antigen 50 microg 50 lymph node metastases 50 HBsAg 50 lymphangiogenesis 50 erythrocyte sedimentation rate 50 selectively binds 50 thyroid carcinomas 50 EGD 50 methyltransferase 50 apical 50 locoregional disease 50 UA NSTEMI 50 cervical lymph node 50 International Prognostic Scoring 50 replicon 50 tumor xenograft models 50 isomerase 50 β2 50 MSSE 50 micrometastases 50 Interrater reliability 50 pulmonary hypertension PH 50 parathyroid carcinoma 50 interferon IFN 50 pT 50 bioavailable testosterone 50 MDA MB 50 multivariate regression analysis 50 intrahepatic cholangiocarcinoma 50 missense mutations 50 transaminase 50 paclitaxel carboplatin 50 voiding dysfunction 50 antiapoptotic 50 prospective nonrandomized 50 locoregional 50 gastrointestinal stromal tumors GISTs 50 Peritoneal 50 Schematic representation 50 sDNA 50 luminal 50 immunochemical fecal occult 50 fluorescein angiography 50 isotope dilution 50 fig. S1 50 immunomodulatory therapy 50 Temsirolimus 50 peptidase 50 WOMAC scores 50 intraclass correlation coefficient 50 hormone receptor negative 50 gastrointestinal stromal tumor GIST 50 potently inhibits 50 Mammotome ® 50 NADiA TM 50 hypoperfusion 50 abnormal cytology 50 Prognostic Index 50 anastomotic leaks 50 Ebstein anomaly 50 subcutaneous immunoglobulin 50 osteochondroma 50 uncemented 50 T1 weighted 50 allogeneic hematopoietic stem cell 50 prognostic indicators 50 methotrexate therapy 50 Self Expanding Stent 50 Qdot 50 Thymic 50 enzyme immunoassay EIA 50 DAS# CRP 50 histopathological examination 50 arterial thromboembolism 50 patientswith 50 mutated KRAS 50 nonischemic 50 macrophage infiltration 50 Non inferiority 50 Monocyte 50 Endovenous 50 SPECT MPI 50 WT1 50 splanchnic 50 serum ferritin 50 Vertebral 50 Fig. 1D 50 skeletally mature patients 50 Myeloid 50 OVATIO 50 homozygosity 50 Kinoid 50 Antigen CEA 50 PCWP 50 hypereosinophilic syndrome 50 unicompartmental knee arthroplasty 50 cotransporter 50 mineralocorticoid receptor 50 chimeric monoclonal antibody 50 receiving Vectibix monotherapy 50 beta 1a 50 hc2 50 Pharmacodynamic 50 apparent diffusion coefficient 50 hydrolase 50 secondary efficacy endpoint 50 EGFR mutant 50 dosing cohort 50 zonation 50 methacholine challenge 50 diameter stenosis 50 malignant neoplasm 50 quantitative RT PCR 50 L#F 50 thyroid nodules 50 homozygote 50 peptide conjugated 50 NSTEMI